Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

NCT01399580 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01399580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01399580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
September 30, 2012
Enrollment
48 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, diabetic nephropathy